Pharvaris N.V. (PHVS)
Nasdaq: PHVS · Pharmaceutical Preparations · Leiden, NL · filing with the SEC since 2020
Who runs Pharvaris N.V.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Modig Berndt
Chief Executive Officer. First filing Mar 2026, latest Sep 21, 2026, 7 filings in all.
Officers reporting now
8
of 13 people with a filing in the last fifteen months
Directors reporting now
5
13 people on the record since 2026
Officerssales are open-market, Nov 12, 2025 to Nov 12, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Lu Peng | President | Mar 2026 | Nov 12, 2026 | 13 · $6.9M |
| Nassif David W. | CFO / CLO | Mar 2026 | Sep 23, 2026 | 2 · $500,000 |
| Modig Berndt | Chief Executive Officer | Mar 2026 | Sep 21, 2026 | 9 · $1.1M |
| Lesage Anne | Chief Early Development | Mar 2026 | Sep 21, 2026 | 19 · $6.7M |
| Abele Stefan Andreas | Chief Technical Ops Officer | Mar 2026 | Sep 17, 2026 | 3 · $2.0M |
| Souverijns Wim | Chief Commercial Officer | Mar 2026 | Sep 16, 2026 | 3 · $1.3M |
| Nijdam Anna | Principal Accounting Officer | Mar 2026 | Jun 8, 2026 | 3 · $300,000 |
| Deschoolmeester Annick | Chief Human Resources Officer | Mar 2026 | Mar 18, 2026 | none |
Directorssales are open-market, Nov 12, 2025 to Nov 12, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Monges Viviane | director | Mar 2026 | Sep 25, 2026 | 2 · $700,000 |
| Schikan Johannes Gerardus Christiaan Petrus | director | Mar 2026 | Sep 24, 2026 | 10 · $9.7M |
| Bjork Elisabeth | director | Mar 2026 | Sep 21, 2026 | 2 · $2.3M |
| Glassman Robert | director | Mar 2026 | Sep 21, 2026 | 5 · $1.5M |
| Meeker David P | director | Mar 2026 | Mar 18, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.